Serial No.:

To Be Assigned

Case No.:

21245YP

Page

3

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-32 without prejudice and insert therefore new Claims 33-50. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-32 (canceled)

- 33. (New) A method for enhancing the quality of sleep in a human patient in need thereof that comprises administering to the patient a therapeutically effective amount of a T-type calcium channel antagonist.
- 34. (New) A method for augmenting sleep maintenance in a human patient in need thereof that comprises administering to the patient a therapeutically effective amount of a T-type calcium channel antagonist.
- 35. (New) A method for treating insomnia in a human patient in need thereof that comprises administering to the patient a therapeutically effective amount of a T-type calcium channel antagonist.
- 36. (New) The method of Claim 33 wherein the T-type calcium channel antagonist is a CNS-penetrant T-type calcium channel antagonist.
- 37. (New) The method of Claim 33 wherein the T-type calcium channel antagonist is a selective T-type calcium channel antagonist.
- 38. (New) The method of Claim 37 wherein the T-type calcium channel antagonist possesses a selectivity for the T-type calcium channel relative to the L-type calcium channel of at least 100 fold as measured by the ratio of IC50 for the T-type calcium channel to the IC50 for the L-type calcium channel as evaluated by the voltage-clamp assay.

Serial No.:

To Be Assigned

Case No.:

21245YP

Page 4

39. (New) The method of Claim 38 wherein the T-type calcium channel antagonist possesses a selectivity for the T-type calcium channel relative to the L-type calcium channel of at least 200 fold as measured by the ratio of IC50 for the T-type calcium channel to the IC50 for the L-type calcium channel as evaluated by the voltage-clamp assay.

- 40. (New) The method of Claim 39 wherein the T-type calcium channel antagonist possesses a selectivity for the T-type calcium channel relative to the L-type calcium channel of at least 500 fold as measured by the ratio of IC50 for the T-type calcium channel to the IC50 for the L-type calcium channel as evaluated by the voltage-clamp assay.
- 41. (New) The method of Claim 33 wherein the T-type calcium channel antagonist possesses a selectivity for the $\alpha 1G$ subtype T-type calcium channel relative to the $\alpha 1H$ subtype and/or $\alpha 1I$ subtype T-type calcium channel of at least 10 fold as measured by the ratio of IC50 for the $\alpha 1G$ subtype T-type calcium channel to the IC50 for the $\alpha 1H$ subtype and/or $\alpha 1I$ subtype T-type calcium channel as evaluated by the voltage-clamp assay.
- 42. (New) The method of Claim 33 wherein the T-type calcium channel antagonist possesses a selectivity for the $\alpha 1H$ subtype T-type calcium channel relative to the $\alpha 1G$ subtype and/or $\alpha 1I$ subtype T-type calcium channel of at least 10 fold as measured by the ratio of IC50 for the $\alpha 1H$ subtype T-type calcium channel to the IC50 for the $\alpha 1G$ subtype and/or $\alpha 1I$ subtype T-type calcium channel as evaluated by the voltage-clamp assay.
- 43. (New) The method of Claim 33 wherein the T-type calcium channel antagonist possesses a selectivity for the $\alpha 1I$ subtype T-type calcium channel relative to the $\alpha 1G$ subtype and/or $\alpha 1H$ subtype T-type calcium channel of at least 10 fold as measured by the ratio of IC50 for the $\alpha 1I$ subtype T-type calcium channel to the IC50 for the $\alpha 1G$ subtype and/or $\alpha 1H$ subtype T-type calcium channel as evaluated by the voltage-clamp assay.
- 44. (New) The method of Claim 33 wherein the T-type calcium channel antagonist possesses an IC50 for binding to the T-type calcium channel of 1 uM or less as evaluated by the T-type calcium channel antagonist voltage-clamp assay.

Serial No.: To Be Assigned

Case No.: 21245YP

Page 5

45. (New) The method of Claim 44 wherein the T-type calcium channel antagonist possesses an IC50 for binding to the T-type calcium channel of 500 nM or less as evaluated by the T-type calcium channel antagonist voltage-clamp assay.

- 46. (New) The method of Claim 45 wherein the T-type calcium channel antagonist possesses an IC50 for binding to the T-type calcium channel of 100 nM or less as evaluated by the T-type calcium channel antagonist voltage-clamp assay.
- 47. (New) The method of Claim 46 wherein the T-type calcium channel antagonist possesses an IC₅₀ for binding to the T-type calcium channel of 50 nM or less as evaluated by the T-type calcium channel antagonist voltage-clamp assay.
- 48. (New) The method of Claim 47 wherein the T-type calcium channel antagonist possesses an IC50 for binding to the T-type calcium channel of 1 nM or less as evaluated by the T-type calcium channel antagonist voltage-clamp assay.
- 49. (New) The method of Claim 33 wherein the T-type calcium channel antagonist is an orally active T-type calcium channel antagonist.
- 50. (New) The method of Claim 33 wherein the T-type calcium channel antagonist is orally administered.